Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma

Lung Cancer: Targets and Therapy · Published 2025-06-01 · DOI 10.2147/lctt.s494990

Authors being retrieved — see the publisher record. https://doi.org/10.2147/lctt.s494990

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study · Lung Cancer: Targets and Therapy · 2025 · Same journal
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer · Lung Cancer: Targets and Therapy · 2025 · Same journal
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report · Lung Cancer: Targets and Therapy · 2025 · Same journal
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions · Lung Cancer: Targets and Therapy · 2024 · Same journal
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival · Lung Cancer: Targets and Therapy · 2025 · Same journal
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker · Lung Cancer: Targets and Therapy · 2025 · Same journal
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code · Lung Cancer: Targets and Therapy · 2023 · Same journal
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer · Lung Cancer: Targets and Therapy · 2026 · Same journal
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834) · Lung Cancer: Targets and Therapy · 2024 · Same journal
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression? · Lung Cancer: Targets and Therapy · 2022 · Same journal